Eyeliss is a proprietary complex of cosmetic ingredients developed specifically for products intended for the care of the skin around the eyes. Although two of its ingredients are peptides, the name Eyeliss refers to a multi-component mixture, not a single peptide molecule. This distinction is fundamental when analyzing cosmetic labels, supplier documentation, and claims regarding ready-made eye creams. 1
Available evidence primarily includes the supplier’s current information on ingredients and a historical summary of cosmetic studies. These documents help identify the commercial material and describe the observed findings. However, they do not confirm that every ready-made cosmetic containing Eyeliss has been evaluated in an independently repeated, fully described controlled study.
Distinguishing between the supplier's declaration and the specific product's declared action is important throughout the analysis.
What is Eyeliss? Names, synonyms, and identity of the ingredient
Eyeliss is offered in conjunction with Sederma, a division of the cosmetics ingredients company Croda.
According to the supplier's current documentation, the liquid mixture contains water, glycerin, hesperidin methyl chalcone, stearate-20, dipeptide-2, and palmitoyl tetrapeptide-7.
The complex is designed for the formulation of cosmetics used topically, especially products for the care of the eye area. 1
The trade name and the list of ingredients according to the international nomenclature of cosmetic ingredients INCI have different functions.
Eyeliss identifies the blend offered by the supplier, whereas the INCI names describe the individual ingredients.
The finished cosmetic product may therefore contain ingredients from the complex without explicitly indicating the trade name.
In turn, the cream advertised as containing Eyeliss does not consist exclusively of this complex. The finished formulation may contain many additional substances.
Croda itself lists a material called Eyeliss PH, with the same INCI ingredients visible in the public documentation.
However, this similarity is not sufficient to confirm identical production specifications, preservation systems, or other technical characteristics of both variants.
This would require current documents relating to a specific version of the product.
In particular, the letter „PH” in the trade name should not be interpreted as a measurement of the pH of the eye cream used by the consumer. 2
In older documents, the name palmitoyl tetrapeptide-3 sometimes appears, while more recent documentation uses the term palmitoyl tetrapeptide-7.
Historical changes in nomenclature can make the related descriptions of ingredients seem inconsistent.
Before claiming that another peptide has been added or the composition has been changed, it is necessary to check the publication date and the chemical context. 3
How is Eyeliss classified? Peptide, protein, mixture, or other substance?
The most precise classification of Eyeliss is a formulated mixture of cosmetic ingredients that contains both peptide and non-peptide substances.
It is not a single protein, a peptide hormone, or a drug administered systemically by injection.
Its use in cosmetics for the eye area should not be interpreted as evidence of approved treatment for ophthalmic or dermatological diseases. 1
The two components belong to the category of peptides: dipeptide-2 and palmitoyl tetrapeptide-7.
Palmitoyl tetrapeptide-7 contains a palmitoyl group of lipid origin, therefore its structure differs from the unmodified tetrapeptide.
Meanwhile, hesperidin methyl chalcone is a non-peptide compound that is chemically related to flavonoids.
Patent literature describes peptide structures using the abbreviations VW and Pal-GQPR. 4
This distinction changes the way the results of the studies are assigned.
The evidence that the formulation containing the entire complex was evaluated does not confirm that any individual peptide was responsible for the measured effect independently.
Without a research project that allows the identification of the contribution of individual components, observed differences may result from the action of the entire mixture, the cosmetic base, or the interaction between the substances or other properties of the formulation.
Peptides used topically in cosmetics should not be confused with peptide drugs acting systemically just because the nomenclature is similar.
The route of exposure, the intended use, the formulation and the appropriate safety assessments vary significantly.
The presence of a peptide component is a chemical description, not evidence of therapeutic equivalence.
The structure and composition of Eyeliss – what has been confirmed?
The entire Eyeliss complex cannot be described using a single amino acid sequence or a single summary pattern.
The individual components can be characterized separately, but assigning a mixture of one peptide sequence or calling it a single „Eyeliss molecule” would lead to confusion between the commercial formulation and the individual chemical substance.
| Component | What does the name denote? | Restriction of interpretation |
|---|---|---|
| Dipeptide-2 | A dipeptide containing two amino acid residues, historically described as valyl-tryptophan | Presence does not determine the level of skin exposure |
| Palmitoyl tetrapeptide-7 | Tetrapeptide modified with a lipid group, described as Pal-GQPR | The modification itself does not prove penetration or benefit |
| Hesperidin methyl chalcone | Non-peptide component associated with flavonoids | Evidence regarding this component cannot be automatically attributed to peptides. |
| Water, glycerin, stearate-20 | Ingredients of the formulated complex | They do not constitute the complete composition of a ready-made cosmetic product |
The current list of ingredients and the historical chemical descriptions confirm this combination.
The exact specifications should be derived from the supplier's current documentation regarding the appropriate version of the material, rather than being reproduced based on an older patent. 1 4
The concentration of the complex and the concentration of the individual peptides
Statements regarding concentration require special caution.
The percentage referring to the supplied Eyeliss mixture is not equivalent to the same percentage of purified dipeptide-2 or palmitoyl tetrapeptide-7.
The supplier's complex contains carrier and auxiliary substances, and the consumer formulation introduces additional ingredients.
Proper reporting therefore requires distinguishing the concentrations of the entire mixture from the concentrations of its individual components.
The INCI list also does not allow determining the amount of each peptide that remains chemically intact after processing and storage.
Stability, compatibility with the other components of the formulation and the composition of the finished product at a specific time are separate issues.
Identifying the ingredient on the label is only the first step in evaluating the material.
Why does the identity of the formulation matter for the interpretation of research studies?
Two products can have the same INCI names, but differ in the quantities of ingredients, production processes, stability, and the way the substance is released from the substrate.
These differences can affect both the measurable cosmetic effect and the likelihood of irritation.
Therefore, the documentation of the supplier’s complex, the list of ingredients of the finished product, and the controlled study of this formulation address three different questions.
None of these sources should be considered a complete substitute for the others.
Scientific studies on Eyeliss – evidence in humans, animals and in the laboratory
Cosmetic observations in humans
The historical summary of Sederma’s research describes cosmetic observations conducted on 20 women aged 40 to 60, who had persistent bags under their eyes.
According to the document, the participants used a gel containing a complex of ingredients for 56 days, and the assessment included three-dimensional measurements of the contour of the skin surface.
On the 56th day, an average reduction in the measured thickness of the bags under the eyes was reported to be 0.20 mm.
The document also states that 70% participants saw a reduction in the volume of bags under their eyes.
These are the results reported by the provider. The available document is not a complete, independently verified clinical publication. 3
The publicly available summary does not sufficiently document random allocation of participants, a comparable group using the same baseline, or blinded evaluation of results.
Without such safeguards, it is not possible to distinguish with sufficient certainty between the observed changes and the influence of the gel matrix, measurement variability, application method, or natural variations in appearance.
Moreover, the statement that 70% participants met the improvement criterion is fundamentally different from the statement that the bags under the eyes decreased by 70%.
Laboratory studies and tissue observations
The provider's archival documentation also summarizes laboratory observations involving an inflammatory marker associated with keratinocytes, an enzymatic test, and an assessment of the permeability of the hair capillaries.
These experiments provide possible explanations for the ingredient concept, but do not directly show that the finished eye cream changes lymphatic drainage or inflammatory activity in people who use the product. 3
To link the mechanism observed in vitro with the apparent cosmetic effect, several questions must be answered in turn.
The appropriate component must remain stable in the product, reach the target biological site, elicit an effect at the achieved exposure level, and contribute to an objectively measured change.
The demonstration of only one of these stages does not confirm the entire causal chain.
What did the studies indexed in PubMed show?
A targeted search in PubMed using the exact trade name Eyeliss did not yield any publications in the review described in the original article.
The result should be interpreted narrowly.
The supplier's archival document provides evidence that the research has been reported, and other work may be indexed under the names of individual components or other formulations.
However, searching by trade name did not yield a separate, indexed clinical publication that would independently and fully confirm the results summarized by the provider.
The analyzed sources also did not confirm the existence of a separate set of animal studies concerning the entire shopping mall.
Even if animal or laboratory studies are available for individual ingredients, their significance should be evaluated based on the material, species, formulation, exposure, and endpoint actually studied.
Results regarding individual components should not be presented as studies of the entire local product.
Evidence regarding ready-made cosmetics
Consumers use complete creams, gels, and serums, rather than the isolated ingredients of the supplier.
For the claim regarding the finished product to be properly interpreted, the evidence should specify the formulation under review, the comparator group, the participants, the conditions of application, the methods of measuring the effects, and observations regarding tolerance.
The study of the commercial complex of ingredients does not automatically confirm the effectiveness of any ready-made cosmetic product that contains this complex.
A well-controlled evaluation should also distinguish between an internal change within the group and a difference that can be attributed to the product under study.
If both the active formulation and the control substrate lead to improvement over time, it is particularly important to compare the results between the groups.
Similarly, measurements of the contour of the skin surface cannot be presented as evidence of a reduction in discoloration or a permanent structural repair if such endpoints were not evaluated.
Swelling under the eyes and other changes in the appearance of the skin
The fullness of the area under the eyes, visible discoloration, and fine wrinkles are not endpoints.
They can occur simultaneously, but each of these problems may have different contributing factors and require different measurements.
The contour observation regarding the appearance of bags under the eyes does not independently confirm changes in skin color or the depth of wrinkles.
Separating these endpoints prevents drawing broad conclusions about „anti-aging of the eye area” from a single, narrow result.
The mechanisms of action of Eyeliss studied scientifically
The proposed scientific rationale for the action of Eyeliss includes vascular permeability, processes related to fluid drainage, and pathways relevant to maintaining skin structure and inflammatory signaling.
In the available evidence, they remain hypotheses or experimental observations, and not confirmed physiological changes in consumers.
Older patent descriptions help to understand the historical rationale for developing the complex, but the patent does not replace controlled clinical validation. 4
The mechanistic interpretation begins with the actually measured endpoint.
The enzymatic activity measured in the test system is not the same as fluid drainage in living tissue.
3D imaging is characterized by external geometry, while the participants' questionnaires record their feelings.
None of these measurements alone does not confirm an improvement in the physiology of the lymphatic system, histological remodeling, or the treatment of the underlying disease.
Since Eyeliss contains many ingredients, the next question is which ingredient or combination of ingredients is responsible for the observed result.
Even the repeatable effect of the finished formulation does not allow determining the causal role of dipeptide-2, palmitoyl tetrapeptide-7, hesperidin methyl chalcone or the vehicle without an appropriate comparative design.
Carefully controlled studies of formulations could help to separate these effects.
A biologically plausible mechanism can support the design of studies and explain why a given cosmetic ingredient was developed.
However, it cannot replace testing the entire formulation under conditions that correspond to its intended use.
Limitations of scientific evidence regarding Eyeliss
The most significant gaps in the evidence include the limited detail of the supplier’s available report, a small trial in humans, an incomplete description of the control procedures, and the lack of an ability to isolate the activity of individual components of the mixture.
The historical document is useful, but it does not contain the full protocol, data at the level of the individual participants, or the statistical analysis information needed for a detailed independent assessment.
The possibility of generalizing the results also limits the selection of participants.
Observations conducted on 20 women aged 40–60 years do not confirm the same effects in other age groups, in men, people with different skin types, or with different causes of changes under the eyes.
Measurements of cosmetic appearance should not be equated with the diagnosis or treatment of a primary disease.
A reliable assessment of the eye area requires maintaining consistent lighting conditions, facial expressions, head positioning, imaging distance, measurement time, and evaluation procedures.
Blindness and previously established measurement principles can reduce the risk of systematic error.
Photographs before and after can illustrate the changes, but without proper controls they do not independently confirm the causal relationship.
Tolerance should be evaluated at the level of the finished cosmetic product.
Formulations may contain preservatives, fragrance substances, surfactants or other ingredients that are important for hypersensitivity and irritation.
Even a favorable result obtained for one tested gel does not mean that every product containing Eyeliss is non-irritating.
It also does not confirm its suitability for direct contact with the surface of the eye.
The proportional evidence suggests that Eyeliss has an identifiable composition described by the supplier and limited documentation of the cosmetic observations reported by it.
More robust claims regarding the magnitude of the effect, causality, durability, and potential for generalization require controlled, clearly described studies of actual ready-made formulations.
Frequently asked questions about Eyeliss
1. Does Eyeliss mean a specific substance?
No. Eyeliss is a brand complex containing several of the listed ingredients. Two of them are related to peptides, while the others perform other chemical functions. This means that the trade names cannot be represented by a single amino acid sequence or a single summary formula; the composition must be checked at both the mixture and the finished product levels. 1 The same trade name may appear in different finished formulations, which is why reliable comparisons still require ingredient lists and documentation of the specific product.
2. What do the available studies on Eyeliss confirm?
They confirm the existence of a cosmetic concept documented by the supplier and limited, reported studies. The available summary of human observations is insufficient to accurately determine the effect attributed to the complex itself compared to a properly selected control group. It allows for describing observations but does not eliminate uncertainties regarding causality, the possibility of generalization, and long-term results. The lack of a specifically described comparator and a complete methodology makes it difficult to reliably estimate the magnitude of the component-specific effect.
3. Are all the ingredients of Eyeliss peptides?
No. The complex also contains non-peptidic substances. Its classification should therefore take into account the full composition, and not just the most characteristic group of components. This is important because the observed effects of the product cannot be automatically attributed to peptides. 1 The scientifically correct description lists the peptide components, but does not present the entire mixture as a compound consisting solely of peptides.
4. Is Eyeliss the same as Haloxyl?
No. Brand names refer to different cosmetic complexes. The presence of common ingredients does not mean that the entire formulations are equivalent. Evidence should be based on the exact composition and the endpoint of the experiment being examined, therefore studies of another complex should not be presented as direct evidence regarding Eyeliss. Before comparing results associated with different brand names, it is necessary to review the studies of specific products and the specifications of the suppliers.
5. Are Eyeliss and Eyeliss PH necessarily identical?
No. The common public INCI list does not confirm identical specifications. The supplier lists both versions, but comparing them requires up-to-date technical documentation. Product names and ingredient lists help identify products, but do not replace full material specifications. 2 Differences in the properties of the individual versions may be significant for the action of the formulation, even if the publicly listed names of the ingredients are the same.
6. Does the declared percentage of the complex correspond to the percentage of peptides?
No. A commercial complex contains more substances than the peptides themselves. Therefore, its percentage in the cream varies from the concentration of each individual peptide. Proper interpretation requires knowledge of both the composition of the mixture and the composition of the finished product. A reliable concentration declaration determines whether it applies to the delivered mixture, the individual component or the final consumer cosmetic.
7. Does the information „70% improvement” mean that the bags under the eyes have decreased by 70%?
No. The percentage of people with improvement determines the proportion of participants meeting the given criterion, not the average magnitude of the change. This distinction should always be verified when the marketing statement transforms the summary of the study into a large percentage figure. The number of participants serving as the basis for calculations and the definition of improvement should accompany each such percentage to avoid exaggerating the results.
8. Does reducing puffiness confirm the effect on dark circles under the eyes?
No. Surface roughness and skin color are different endpoints. The study should measure the problem that it claims to improve using the appropriate method. Improvement of one parameter does not automatically confirm improvement of the other, even if both affect the appearance of the same area. Cosmetic claims should therefore specify whether they relate to contour, swelling, skin color, or any other separately assessed feature.
9. Can the before and after photos prove the effectiveness of Eyeliss?
No. The photographs alone do not allow causality to be established. Lighting, facial expressions, camera settings, position, and natural variability can all influence the appearance. Standardized imaging is useful in controlled studies, but a convincing photograph in itself does not constitute a reliable estimate of the effectiveness of the component. Constant imaging conditions and an appropriate comparison group are needed to separate the product effect from ordinary photographic differences.
10. Does the result of the cellular test confirm the improvement in lymphatic drainage in humans?
No. A cellular or enzymatic test does not directly measure the functioning of the human lymphatic system. Confirmation of such a claim would require appropriate measurements of exposure and physiology. A credible mechanism remains a hypothesis until proper experiments link it to the proposed effect in humans. Laboratory observation provides a mechanistic context, while the proposed physiological effect in users remains a separate question.
11. Does palmitylation indicate that the peptide reaches the site of action?
No. The addition of a lipid group in itself does not confirm the delivery of the substance from a finished cosmetic product. Penetration depends on the entire formulation and the biological barrier. Therefore, the claim regarding reaching the target requires evidence of exposure, not merely inference from the name of the ingredient. Stability and local availability also depend on the vehicle, application conditions, and the properties of the skin barrier.
12. Does the testing of one Eyeliss cream confirm the effectiveness of another cream?
Not automatically, because formulations can differ in concentration, base, stability, and other components. Evidence regarding one product may support a hypothesis regarding another, but direct equivalence requires justification. The finished product remains the appropriate unit of assessment for the claim about the product. Before generalizing the result to various cosmetics, measurements of effects and tolerability regarding specific formulations are needed.
13. Does immediate skin smoothing mean its structural reconstruction?
No. A change in appearance does not unequivocally indicate a biological cause. Superficial effects and long-term tissue changes require different measurements. The claim of structural remodeling requires evidence related to structure and durability, not short-term photography or subjective perception. A temporary optical or moisturizing effect can change appearance without demonstrating a lasting change in tissue architecture.
14. Does the patent confirm the clinical effectiveness of Eyeliss?
No. A patent documents the invention and the scope of the claimed claims. It is not equivalent to controlled clinical evaluation or independent replication of results. Patent information can help identify ingredients and proposed mechanisms, but claims of efficacy still require appropriate experimental evidence. 4 Patent claims can help to trace the history of a component's concept, but they should not be counted as independently replicated clinical results.
15. Are all Eyeliss products automatically non-irritating?
No. Tolerance depends on the full formulation and the person who comes into contact with it. The mere presence of a component does not rule out irritation or hypersensitivity to other substances. A useful study should record adverse events under appropriate conditions of use, rather than assuming safety based on the presence of the peptide. The irritant potential should be evaluated based on the actual formulation and its intended use, rather than inferring from a favorable description of the component.
16. Is an eye cream suitable for use inside the eye as well?
No. The intended use for the skin surrounding the eyes differs from direct exposure of the eye surface. Evidence regarding one use does not confirm the other. The declared intended use of a product and the safety assessment of a specific formulation set the fundamental limits for the interpretation of cosmetic claims. Products intended for the skin surrounding the eyes do not need to be developed or tested for application on the surface of the eye.
17. How should a more reliable Eyeliss study look like?
A more reliable study would compare a precisely defined ready-made formulation with an appropriately selected control group. It should previously specify endpoints, use blinded assessment where possible, document the course of the participants’ participation and tolerance, and report both the mean changes and the uncertainty of the estimates. Independent replication of the results would help determine the repeatability of the cosmetic effect. Publication of the protocol, the composition of the control formulation, the effect estimates, the confidence intervals, and the results regarding adverse events would facilitate assessment and replication of the studies.
Conclusions
Eyeliss is a proprietary cosmetic blend containing two peptide ingredients and non-peptidic substances, rather than a single molecule with a single amino acid sequence.
Its sales composition was documented, and the provider's archival summary describes the changes in the selected measurements of the contour of the eye area.
However, the available evidence in humans is limited in number and not fully described.
They do not allow for a clear determination of the contribution of the complex itself to the observed effect, nor do they confirm the activity of each finished product that contains it.
A responsible interpretation requires a clear indication of the measured cosmetic effect, the formulation being tested, and the limitations of the project.
Additional controlled studies of finished products, subject to independent evaluation, would provide a stronger basis for formulating statements about the repeatability and clinical significance of the results.
Educational warning regarding the safety of cosmetics and regulations
The article is purely educational and scientifically informational in nature. It does not constitute medical advice, ophthalmological evaluation, or recommendations for the purchase or use of a particular cosmetic product. It does not diagnose the causes of swelling, discoloration, or irritation of the eye area and does not replace consultation with a qualified medical staff, especially when symptoms are persistent, new, painful, or alarming. Eyeliss is a complex of cosmetic ingredients and not an approved drug for the treatment of eye diseases, disorders of lymphatic function, inflammatory conditions, or other conditions. Laboratory experiments, patent descriptions, and cosmetic observations reported by the supplier do not confirm therapeutic efficacy. Results regarding a single gel or product cannot be automatically applied to all ready-made cosmetics containing similar INCI ingredients. The skin around the eyes differs from the surface of the eyeball, therefore a product intended for external care of this area does not necessarily need to be suitable for direct contact with the eye. Safety and the risk of irritation depend on the complete formulation, the individual characteristics of the user, and the intended use of the product. Labeling, current manufacturer's instructions, and relevant local regulations regarding cosmetics should be taken into account. All statements made by the supplier are presented as information derived from sources and not independently verified clinical studies. This article does not contain an individual protocol of use or a guarantee that a particular product is effective, non-irritating, or medically appropriate.
References
- Croda Beauty. (n.d.). Eyeliss™ [Manufacturer ingredient description]. Retrieved October 23, 2026, from https://www.crodabeauty.com/en-gb/products/product/2986-eyeliss
- Croda Beauty. (n.d.). Eyeliss™ PH [Manufacturer ingredient description]. Retrieved October 23, 2026, from https://www.crodabeauty.com/en-gb/products/product/2987-eyeliss_1_ph
- Sederma. (2006, March). Eyeliss: Treatment of bags—Claim substantiation (Version 2) [Manufacturer technical sheet; archived transcription reproduced within “Get White Papers—Bio”]. https://doczz.net/doc/1394680/get-white-papers—bio
- Pinnell, S. R. (2007). Skin-care composition (U.S. Patent No. 7,160,560). https://patents.google.com/patent/US7160560B2/en